Scholarlink

<p>Digital measures of walking and sedentariness may objectively quantify Parkinson’s disease (PD) progression. We analyzed longitudinal wearable-sensor data to evaluate the sensitivity and specificity of digital walking and non-walking measures in ambulatory people with PD. We selected 26 individual and 6 composite measures with sufficient sensitivity and test-retest reliability in a development dataset (<i>N</i> = 171). Twenty measures showed significant within-participant changes, and 7 showed larger 2-year effect-size than gold-standard clinical measures in people with early-stage PD (<i>N</i> = 101, mean number of years since diagnosis [YSD], 2.2). Significant changes in non-walking and composite measures were detectable as early as 10 months. Twelve measures showed greater change in people with more advanced PD (<i>N</i> = 67; mean YSD 6.5) compared to matched non-PD individuals (<i>N</i> = 171). Sensitivity and specificity results indicate that measures capturing walking and especially non-walking behaviors hold promise as PD progression markers in early to mid-stage PD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Wearable-sensor based walking and non-walking measures as progression markers in early to mid-stage Parkinson’s disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月18日

查看全文
  • King Chung Ho,
  • Siying Li,
  • Claudia Serrano-Amenos,
  • Nathan Kowahl,
  • Erin Rainaldi,
  • Chen Chen,
  • Bastiaan R. Bloem,
  • Laurie H. Sanders,
  • Ludy C. Shih,
  • Andrew Siderowf,
  • William J. Marks Jr,
  • Ritu Kapur,
  • Luc J. W. Evers,
  • Sooyoon Shin

摘要

Digital measures of walking and sedentariness may objectively quantify Parkinson’s disease (PD) progression. We analyzed longitudinal wearable-sensor data to evaluate the sensitivity and specificity of digital walking and non-walking measures in ambulatory people with PD. We selected 26 individual and 6 composite measures with sufficient sensitivity and test-retest reliability in a development dataset (N = 171). Twenty measures showed significant within-participant changes, and 7 showed larger 2-year effect-size than gold-standard clinical measures in people with early-stage PD (N = 101, mean number of years since diagnosis [YSD], 2.2). Significant changes in non-walking and composite measures were detectable as early as 10 months. Twelve measures showed greater change in people with more advanced PD (N = 67; mean YSD 6.5) compared to matched non-PD individuals (N = 171). Sensitivity and specificity results indicate that measures capturing walking and especially non-walking behaviors hold promise as PD progression markers in early to mid-stage PD.